05 Aug Bio-Me´s PMP™ platform demonstrates its diagnostic and prognostic applicability in pediatric IBD

PMP™ was used to profile the gut microbiome of children and discriminate between inflammatory bowel disease (IBD), symptomatic non-IBD, and healthy children, but also between ulcerative colitis (UC) and Crohn’s disease (CD) phenotypes.

OSLO, Norway, August 05, 2022 – A recent study explored the fecal microbiome of treatment-naïve pediatric IBD patients (CD, N=80; UC, N=27), symptomatic non-IBD patients (N = 50), and healthy children (N = 75). Fecal samples were analyzed with Bio-Me’s Precision Microbiome Profiling (PMP^™) platform for determining the absolute quantification of ~100 prevalent and well-characterized bacterial targets. The study was conducted in Norway in a collaboration between Akershus University Hospital, Oslo Metropolitan University, and the Norwegian Institute of Public Health.

The study demonstrated a significantly reduced bacterial abundance in IBD and symptomatic non-IBD patients compared to healthy children, a lower abundance of Bifidobacterium species in CD compared to UC patients, and a lower abundance of butyrate-producing bacteria in IBD patients in need of biologic therapy. Diagnostic, Phenotype and Prognostic Indexes were constructed with very good discriminating properties:

The authors stated that PMP^™ could be a clinically suitable tool with the capacity to generate results within hours.

Morten Isaksen, founder and Chief Innovation Officer of Bio-Me comments: “To my knowledge, this is the first time we have seen such strong discriminations through the gut microbiome profile in pediatric IBD. Importantly, this study demonstrates the clinical potential of our PMP^™ platform and its applicability in IBD research”.

Link to the publication: https://www.mdpi.com/2076-2607/10/7/1273.